肝硬化对接受维持性血液透析患者预后的影响
无肝硬化患者2年生存率71.7%,高于肝硬化患者的54.4%(P<0.0001)。失代偿期肝硬化患者2年生存率44.1%,低于代偿期肝硬化(62.8%,P=0.002)和无肝硬化患者(71.7%,P<0.0001)。代偿期和失代偿期肝硬化均为2年死亡的独立预测因素。
要点
- 血液透析患者中,肝硬化患者2年生存率54.4%,低于无肝硬化患者的71.7%。
- 失代偿期肝硬化患者2年生存率44.1%,低于代偿期肝硬化(62.8%)和无肝硬化患者(71.7%)。
- Child-Pugh A级患者2年生存率65.5%,高于B级(27.7%)和C级(0%)。
核心结论
- 肝硬化与血液透析患者死亡率独立相关,严重肝硬化患者2年预后差。
- 决定开始肾脏替代治疗时,应考虑肝硬化严重程度和肝外合并症。
研究设计与样本
- 回顾性(2000年1月1日至2004年12月31日)和前瞻性(2005年1月1日至2014年12月31日)纳入法国某地区接受血液透析的终末期肾衰竭患者。
- 主要终点为2年生存率。
主要发现
- 无肝硬化患者2年生存率71.7%,高于肝硬化患者的54.4%(P<0.0001)。
- 失代偿期肝硬化患者2年生存率44.1%,低于代偿期肝硬化患者的62.8%(P=0.002)和无肝硬化患者的71.7%(P<0.0001)。
- 代偿期和失代偿期肝硬化均为2年死亡率的独立预测因素。
- 在仅限肝硬化患者的敏感性分析中,Child-Pugh A级患者2年生存率65.5%,高于B级的27.7%和C级的0%(P<0.0001)。
- 基于严重程度评分(MELD和Child-Pugh)和肝外合并症的预测模型可正确分类约70%患者的死亡风险。
关键数值与推荐
- 无肝硬化患者2年生存率71.7% vs 肝硬化患者54.4%(P<0.0001)。
- 失代偿期肝硬化患者2年生存率44.1% vs 代偿期肝硬化患者62.8%(P=0.002) vs 无肝硬化患者71.7%(P<0.0001)。
- Child-Pugh A级患者2年生存率65.5% vs B级27.7% vs C级0%(P<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Further study is needed on the prognostic impact of cirrhosis on haemodialysis patients. AIM: To evaluate cirrhosis' impact according to severity on survival and to provide therapeutic guidelines for haemodialysis cirrhotic patients. METHODS: Patients with end-stage renal failure treated with haemodialysis were included retrospectively from 01/01/2000 to 31/12/2004 and prospectively from 01/01/2005 to 31/12/2014 in our French Region. Clinical data, presence of cirrhosis and its severity were recorded at the beginning of haemodialysis. The primary endpoint was 2-year survival. RESULTS: Seven thousand three hundred and fifty-four patients (96%) without cirrhosis and 304 patients (4%) with cirrhosis were included. Two-year survival in noncirrhotic patients was higher than in cirrhotic patients (71.7% vs 54.4%, P < 0.0001). Patients with decompensated cirrhosis had a worse 2-year outcome (44.1%) as compared to compensated cirrhotic (62.8%, P = 0.002) and noncirrhotic patients (71.7%, P < 0.0001). Compensated and decompensated cirrhosis were independent predictive factors of 2-year mortality. In sensitivity analysis restricted to cirrhotic patients, 2-year survival of Child-Pugh A patients was higher than in Child-Pugh B and C patients (65.5% vs 27.7% vs 0%, P < 0.0001). Development of predictive models based either on severity scores (MELD and Child-Pugh) and extrahepatic comorbidities allowed correct classification of around 70% of patients in terms of mortality and may help to better stratify mortality risk in this population. CONCLUSIONS: Cirrhosis is independently associated with mortality in haemodialysis patients. Patients with severe cirrhosis have a poor 2-year outcome. Severity of cirrhosis and presence of extrahepatic comorbidities should be considered when deciding to initiate renal replacement therapy.
引用
- Artru F, Louvet A, Glowacki F, et al. The prognostic impact of cirrhosis on patients receiving maintenance haemodialysis. Aliment Pharmacol Ther. 2019. PMID: 31087566. doi:10.1111/apt.15279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。